These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

543 related items for PubMed ID: 17900686

  • 21. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
    Bianchini M, De Brasi C, Gargallo P, Gonzalez M, Bengió R, Larripa I.
    Eur J Haematol; 2009 Apr; 82(4):292-300. PubMed ID: 19191867
    [Abstract] [Full Text] [Related]

  • 22. Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway.
    Markova B, Albers C, Breitenbuecher F, Melo JV, Brümmendorf TH, Heidel F, Lipka D, Duyster J, Huber C, Fischer T.
    Oncogene; 2010 Feb 04; 29(5):739-51. PubMed ID: 19881535
    [Abstract] [Full Text] [Related]

  • 23. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
    Branford S, Seymour JF, Grigg A, Arthur C, Rudzki Z, Lynch K, Hughes T.
    Clin Cancer Res; 2007 Dec 01; 13(23):7080-5. PubMed ID: 18056186
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Prolonged treatment with imatinib mesylate in patients with advanced chronic myeloid leukemia causes a reduction of bcr/abl mRNA levels independent of cytogenetic response.
    Cariani E, Capucci M, Micheletti M, Spalenza F, Zanella I, Albertini A, Rossi G.
    Ann Hematol; 2003 Jun 01; 82(6):333-5. PubMed ID: 12734675
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.
    Nimmanapalli R, Bhalla K.
    Oncogene; 2002 Dec 09; 21(56):8584-90. PubMed ID: 12476305
    [Abstract] [Full Text] [Related]

  • 31. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
    Ebos JM, Tran J, Master Z, Dumont D, Melo JV, Buchdunger E, Kerbel RS.
    Mol Cancer Res; 2002 Dec 09; 1(2):89-95. PubMed ID: 12496355
    [Abstract] [Full Text] [Related]

  • 32. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
    Park SJ, Kim MJ, Kim HB, Kang CD, Kim SH.
    Biochem J; 2009 Apr 28; 420(1):73-81. PubMed ID: 19203346
    [Abstract] [Full Text] [Related]

  • 33. Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo.
    Miething C, Mugler C, Grundler R, Hoepfl J, Bai RY, Peschel C, Duyster J.
    Leukemia; 2003 Sep 28; 17(9):1695-9. PubMed ID: 12970766
    [Abstract] [Full Text] [Related]

  • 34. [Study on mismatch repair genes of chronic myeloid leukemia].
    Luo J, Peng ZG, Chen Y, Lai YR, Lu YY, Song SJ.
    Zhonghua Xue Ye Xue Za Zhi; 2006 Feb 28; 27(2):103-6. PubMed ID: 16732964
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.
    Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST.
    Cancer Res; 2003 Sep 15; 63(18):5716-22. PubMed ID: 14522890
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.